Advances in prostate cancer

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 226-235

  Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ESTRAMUSTINE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BONE PAIN; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 0032892737     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00016     Document Type: Review

References (73)

1. Gronberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, et al: Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997, 57:4707-4709
2. Bratt O, Kristofferson U, Lundgren R, Olsson H: The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: A population-based cohort study. Eur J Cancer 1997, 33:2237-2240
3. Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH: Familial prostate cancer: A different disease? J Urol 1997, 158:2197-2201. This study evaluated outcome in patients who had a positive family history for prostate cancer and suggested that patients with familial prostate cancer had a higher likelihood of biochemical failure after radical prostatectomy than patients with sporadic cancer. This study raises the important question of whether familial prostate cancers may be more biologically aggressive than sporadic cancers
4. Bauer JJ, Srivastava S, Connelly RR, Sesterhenn IA, Preston DM, McLeod DG, Moul JW: Significance of familial history of prostate cancer to traditional prognostic vaiables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998, 51:970-976
5. Vijayakumar S, Winter K, Sause W, Gallagher MJ, Michalski J, Roach M III, et al: Prostate specific antigen levels are higher in African-American than in white patients in a multicenter registration study: Results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998, 40:17-25
6. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, et al: Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998, 16:3101-3104. This important study identifies low literacy as an overlooked but significant barrier to the diagnosis of early-stage prostate cancer, which appears to cut across race. After adjustment for differences in literacy, age, and geographic location, race was not a significant predictor of advanced-stage prostate cancer at diagnosis
7. deVere White RW, Deitch AD, Jackson AG, Gandour-Edwards R, Marshalleck J, Soares SE, et al: Racial differences in clinically localized prostate cancers of black and white men. J Urol 1998, 159:1979-1982
8. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, et al: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998, 58:1620-1623
9. Fair WR, Fleshner NE, Heston W: Cancer of the prostate: A nutritional disease? Urology 1997, 50:840-848
10. Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, et al: Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 1997, 89:1716-1720. This epidemiologic study suggests that prostate cancer prevalence is higher in Japanese-American men compared with Japanese men in Japan but not as high as the difference in incidence of prostate cancer, suggesting that at least part of the increase in prostate cancer rates among Japanese-American men in the United States reflects more intensive prostate cancer screening in the United States than in Japan. Nevertheless, this study calls into question the role of environment and diet
11. Veirod MB, Laake P, Thelle DS: Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997, 73:634-638
12. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440-446. This controlled clinical trial confirms previous epidemiologic studies suggesting that vitamin E may slow or decrease the development of prostate cancer. Long-term supplementation of subjects in this study with α-tocopherol substantially reduced prostate cancer incidence and mortality. A key unresolved question is whether vitamin E supplementation can slow the progression of prostate cancer
13. Macintosh CA, Stower M, Reid N, Maitland NJ: Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998, 58:23-28. This laboratory study suggests that phenotypically similar tumor foci from the same patient can have markedly different genotypes. This study confirms that prostate cancer is a multiclonal event and that conclusions reached from a single focus of prostate cancer may be difficult to generalize
14. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al: Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998, 90:233-237. This is another study that points out that patients with more than one focus of prostate cancer may, in fact, harbor more than one genetically distinct clone.
15. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57:4997-5000
16. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, et al: BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998, 16:3069-3082
17. Yeh S, Miyamoto H, Shima H, Chang C: From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A 1998, 95:5527-5532
18. Wingo PA, Landis S, Ries L: An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 1997, 80:1810-1813. This is a notable report because it is the first time in which the incidence of prostate cancer has actually declined. Almost certainly, this reflects the culling out of long latent as well as more recent cancers, accounting for a transient rapid increase in incidence rates, followed by a decline
19. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52:448-449. This study evaluates trends in age at diagnosis and age-adjusted trends in stage and grade at diagnosis in the SEER database, during the time period that screening was initiated. Results suggest a significant downward trend in age at diagnosis and downward shift in stage of disease at diagnosis, starting with the advent of the PSA era
20. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW: Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 1998, 51:186-195
21. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547. This large multicenter prospective clinical trial evaluates the utility of percentage of free PSA as an independent predictor of the presence of prostate cancer in a screening program and provides recommendations for cutoff values
22. Catalona WJ, Beiser JA, Smith DS: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997, 158:2162-2167
23. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771
24. 3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol 1998, 16:3094-3100. This important study uses prostate cancer volume as a pretreatment predictor of poor outcome. Although prostate cancer volume appears to identify patients with localized prostate cancer who have a poor prognosis, this risk assessment schema requires prospective validation with an independent data set.
25. Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H: Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998, 159:2023-2029
26. Noldus J, Graefen M, Huland E, Busch C, Mammerer P, Huland H: The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 1998, 159:2007-2008
27. D'Amico AV, Schnall M, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A: Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998, 51:449-454
28. Ismail M, Petersen RO, Alexander AA, Newschaffer C, Gomella LG: Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 1997, 50:906-912
29. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Murace PJ, Ross JS: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998, 16:1302-1309
30. Wood DP Jr, Banerjee M: Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997, 15:3451-3457
31. Herold DM, Hanlon AL, Movsas B, Hanks GE: Age-related prostate cancer metastases. Urology 1998, 51:985-990
32. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974. This controversial retrospective cohort study of outcome data in patients treated with radical prostatectomy, brachytherapy, or three-dimensional conformal external-beam radiation concludes that brachytherapy (radioactive seed implantation) has an inferior outcome in intermediate-risk and high-risk patients. Although there are significant problems with this study, it raises important questions about the efficacy of brachytherapy, which warrant prospective, randomized clinical trials
33. Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, Pilepich MV: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG £77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998, 40:769-782
34. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA: Dose escalation with 3D conformal treatment: five-year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998, 41:501-510. This large trial demonstrates a radiation dose response in patients with localized disease and a PSA greater than 10 treated with three-dimensional conformal radiotherapy
35. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500. Similar to the study by Hanks et al. (Int J Radiat Oncol Biol Phys 1998, 41:501-510), these data provide evidence for a significant effect of dose escalation and argues that non-dose-escalated therapy, particularly in intermediate-risk and high-risk prostate cancer patients, should be considered outmoded and inadequate therapy
36. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV: Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92
37. Beard CJ, Lamb C, Buswell L, Schneider L, Propert KJ, Gladstone D, et al: Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:257-262
38. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al: Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998, 159:2013-2016
39. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280:975-980. This analysis of patients with localized prostate cancer managed with watchful waiting suggests that watchful waiting is not an option for patients with Gleason score 7 to 10. Watchful waiting may be appropriate for some patients with Gleason score 2 to 4. In the intermediate group of patients with Gleason score 5 or 6, watchful waiting can be considered only in patients who have a life expectancy of less than 10 to 15 years. In the absence of a randomized clinical trial, this analysis provides a set of tables and graphs that can be used for counseling patients on the risks involved in watchful waiting
40. McLaren DB, McKenzie M, Duncan G, Pickles T: Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998, 82:342-348
41. Adolfsson J, Steineck G, Hedlund PO: Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997, 50:722-726
42. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998, 160:1387-1391
43. Leibman BD, Dillioglugil O, Scardino PT, Abbas F, Rogers E, Wolfinger RD, Kattan MW: Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis. J Clin Oncol 1998, 16:2267-2271. This article suggests that the rate of growth of cancers, at least as indicated by PSA doubling time, is identical following radiation and radical prostatectomy after the first 2 years beyond therapy. These are important data for subsequent intervention studies
44. Grossfeld GD, Stier DM. Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR: Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 1998, 160:1398-1404
45. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY, Kelly MD: Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997, 39:681-686
46. Raymond JF, Vuong M, Russell KJ: Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 1998, 41:93-99
47. Tefilli MV, Cheiler EL, Tiguert R, Banerjee M, Forman J, Pontes JE, Wood DP Jr: Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. Urology 1998, 52:224-229
48. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, Pontes JE, Wood DP Jr: Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998, 51:789-795
49. Fowler JE Jr, Bigler SA, Kolski JM, Yee DT: Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 1998, 82:1112-1117. This is the first study to evaluate the utility of androgen deprivation alone as primary hormone therapy for patients with locally advanced cancers with follow-up to 3 to 5 years after initiation of therapy
50. van den Ouden D, Hop WC, Schroder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160:1392-1397
51. Petrovich Z, Lieskovsky G, Langholz B, Formenti S, Baert L, Streeter O, Skinner DG: Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998, 40:139-147. This reasonably large study of adjuvant radiotherapy after prostatectomy given for patients with T3 tumors reports a surprisingly high (83%) 10-year actuarial survival
52. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW: Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer 1998, 82:1909-1914
53. Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L: Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology 1998, 51:782-787
54. Hanks GE, Buzydlowski J, Sause WT, Emami B, Rubin P, Parsons JA, et al: Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys 1998, 40:765-768. This study is important for its negative results, suggesting that radiation therapy to the prostate and pelvis in lymph node-positive patients is inadequate therapy. The addition of other therapies, such as androgen deprivation, appears to be critical
55. Whittington R, Malkowicz SB, Machtay M, Van Arsdalen K, Barnes MM, Broderick GA, Wein AJ: The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer. Int J Radiat Oncol Biol Phys 1997, 39:673-680
56. Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998, 159:2030-2034. In this small randomized study, patients with localized prostate cancer with or without nodal involvement received either radiation alone or radiation plus androgen deprivation. Despite a crossover arm, the initial radiation plus hormones arm revealed a significant increase in overall and disease-specific survival. These differences held only for patients with node-positive disease and suggest that early androgen deprivation (as previously shown by the Medical Research Council in patients with more advanced disease) is probably warranted
57. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997, 79:235-246
58. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042. This article suggests that orchiectomy plus flutamide compared with orchiectomy plus to delayed addition of flutamide at progression offers no survival advantage to patients with metastatic prostate cancer. This large, well-designed study calls into question the utility of CAB, although it is at variance with a similarly well-designed study from the same group, reported in 1989
59. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997, 50:330-336
60. Grossfeld GD. Small EJ, Carroll PR: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998, 51:137-144. This study begins to characterize the utility of intermittent androgen therapy in patients with local or locally advanced prostate cancers. The study suggests that this approach is feasible, although confirmatory randomized trials are warranted
61. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998, 160:1220-1229. This is an excellent review of definitions of hormone refractory prostate cancer and the stepwise evaluation and treatment of these patients
62. Smith DC, Rodman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998, 52:257-260
63. Dawson NA: Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 1998, 16:3398-3405
64. Small EJ, Baron A, Bok RA: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997, 80:1755-1759
65. Sartor O, Weinberger M, Moore A, Li A, Figg WD: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998, 52:252-256
66. Smith DC, Dunn RL, Strawderman MS, Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998, 16:1835-1843
67. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997, 50:754-758
68. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, et al: A phase II trial or oral estramustine and oral etoposide in hormone retractory prostate cancer. Urology 1997, 50:401-406
69. Tannock I, Osoba D, Stockler M, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized study with palliative end points. J Clin Oncol 1996, 14:1756-1764
70. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, et al: Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998, 16:2272-2279
71. Adami S: Bisphosphonates in prostate carcinoma. Cancer 1997, 80(8 suppl):1674-1679
72. Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I: Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997, 76:939-942
73. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998, 339:783-791